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To the editor 
Physical activity (PA) is a relevant outcome measure in COPD. Low PA is prevalent and drives 
prognosis [1]. Unfortunately, the determinants of PA and its change over time are poorly 
understood [1]. The fact that the PA progressively declines over time along with worsening of lung 
function and health status [2], suggests that the PA decline could be due to the progression of the 
disease and specifically to acute exacerbations [3]. An acute reduction in PA at the onset has been 
reported both in severe exacerbations requiring a hospitalization [4] and in ambulatory treated 
exacerbations [5,6]. A sustained PA reduction has been shown one month after hospital discharge 
[4] whereas PA almost returns to stable levels after community treated exacerbations [6]. One study 
found faster PA decline in patients with a history of ≥2 exacerbations in the 12 months prior to the 
study [5]. This analysis did not adjust for confounders of the association (e.g. airflow obstruction, 
symptom burden) or external variables influencing PA (e.g. climate). It could also be argued that the 
greater decline in PA was due to lower health status at baseline. Although PA is an important 
outcome for COPD patients, little is known about the role of exacerbations on patients’ experience 
of PA. Importantly, both the amount of activity and difficulties experienced during activity are 
integral to the concept of PA limitation [7]. The aim of the present analysis was to assess the 
association between the number and severity of exacerbations and changes in PA and PA experience.  
As part of the IMI-JU PROactive study [7,8], patients with COPD from mixed healthcare settings 
(tertiary hospitals, rehabilitation centres and primary care) in 5 European centres [Athens (Greece), 
Edinburgh and London (UK), Leuven (Belgium) and Groningen (The Netherlands)] were studied at 
baseline and at 12 months follow-up. Patients followed and those lost to follow-up were comparable. 
Objective PA was measured using the Dynaport Movemonitor accelerometer (McRoberts BV, The 
Hague, The Netherlands). The main PA outcome analysed was the change (difference between 
baseline and one year) in daily step count, the secondary outcome was the change in intensity 
during locomotion. Patient experience of PA was assessed with the Clinical visit PROactive Physical 
Activity in COPD (C-PPAC) instrument [7], which consists of a total score and amount and difficulty 
scores. The number and severity of COPD exacerbations during the 12-month follow-up was 
retrieved [8]. We defined exacerbations as moderate (treated in an ambulatory setting with 
systemic antibiotics and/or systemic glucocorticosteroids) or severe (requiring hospital admission), 
following the GOLD initiative guidelines [9]. In addition to the number of exacerbations, we 
generated a variable combining the number and the severity of exacerbations. The association 
between exacerbation variables and PA change was analysed using regression analysis adjusted for 
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baseline PA values. To remove the effect of potential confounders (see footnote Figure 1) we built 
a multivariable linear model for each PA outcome. Sensitivity analyses were performed excluding 
patients (i) with a COPD admission in the year before recruitment, (ii) with extreme PA values (≤5th 
or ≥95th percentiles) and (iii) with a COPD admission 2 months prior to the final measurement to 
exclude an acute effect. As post hoc explanatory analyses we tested the (bivariate) association 
between exacerbation variables and change in FEV1, 6MWD and mMRC, adjusted for baseline. All 
statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). 
 
The present analysis is based on 141 patients with valid data at baseline and follow-up (75% male, 
with a mean (SD) of 67 (8) years, 27 (5) kg.m-2 BMI, 59 (21) % predicted FEV1) of whom eighty-one 
(57%) experienced at least one exacerbation during follow-up. In the whole group there was a small, 
non-significant decline in step count [5209 (3050) steps.day-1 at baseline vs 5019 (3099) steps.day-1 
at follow-up]; while movement intensity [1.82 (0.26) m.s-2 at baseline vs 1.80 (0.28) m.s-2 at follow-
up], exercise capacity [452 (119) m at baseline vs 450 (123) m at follow-up] and FEV1 [1.62 (0.69) l 
at baseline vs 1.63 (0.69) l at follow-up] did not change. Patients had a baseline mean C-PPAC total 
score of 69 (13), with domain scores for amount and difficulty 64 (16) and 74 (15), respectively. 
The number of exacerbations was related to the decline in steps.day-1. In the multivariable model, 
a mean (SE) change of 251 (207), -144 (262) and -797 (244) steps.day-1 was observed in patients who 
had presented no, one, or two or more exacerbations during follow-up respectively (Figure 1A). 
Patients experiencing two or more moderate exacerbations (-753 steps.day-1) and those 
experiencing at least one severe exacerbation (-705 steps.day-1), showed a larger decline in PA than 
those with no exacerbations (Figure 1B). There was no association between exacerbations during 
follow-up and changes in PA intensity (m.s-2). In relation to patient experience of PA, Figure 1 (C,E) 
shows that patients with 2 or more exacerbations suffered more deterioration in C-PPAC amount (-
4.2 points) and difficulty (-1.9 points) scores compared to patients having no or only one 
exacerbation. Patients experiencing two or more moderate exacerbations or at least one severe 
exacerbation showed a larger decline in C-PPAC amount and difficulty scores than those with no 
exacerbations, however some of these associations were not statistically significant (Figure 1 D,F). 
All sensitivity analyses yielded comparable results. Having exacerbations was related to a significant 
(p<0.01) larger increase in mMRC score but not to changes in 6MWD or FEV1.  
The present analyses show that the acute drop in PA after an exacerbation [4,5,6] has an important 
and lasting effect that cannot be attributed to confounders or baseline PA. A higher exacerbation 
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frequency was, as expected, associated with a more pronounced PA decline. Patients with frequent 
exacerbations constitute a specific disease phenotype with a worse prognosis, specifically a faster 
loss in lung function [10], a greater worsening of health status [11] and a substantial reduction in 
the amount of PA (-797 steps.day-1) as indicated by our findings. An unexpected finding from this 
study is that two or more moderate events result in a long-term decline that is clinically relevant 
[12] and equivalent to that of a severe event, confirming the importance of prevention and early 
management of exacerbations regardless of the severity [9].  
The fact that exacerbations result in a decrease in the amount of PA can be interpreted as part of 
the multiple systemic consequences [9]. First, we could hypothesize that the decline is a 
consequence of a loss in exercise capacity. Against this hypothesis, our data fail to show an 
association between exacerbations during follow-up and changes in exercise capacity. Second, the 
PA decline could potentially be explained based on a worsening of symptoms during an exacerbation 
leading to more inactivity, bringing patients in a vicious cycle of symptoms and inactivity [13]. Based 
on our explanatory analysis showing an association between exacerbations and an increase in 
dyspnoea, the latter hypothesis would be a plausible mechanism.  
The present results have important implications for daily clinical practice and underscore the 
importance of identifying frequent exacerbators, as supported by the combined GOLD classification 
[9]. Our results support the promotion of interventions to increase PA, such as coaching programs 
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Figure 1. Decline in steps.day-1 (A-B) and C-PPAC instrument (D-F) according to COPD exacerbations in the 12-m follow-up 
(multivariable linear regression).  
Data presented as estimated marginal means (Least squares means) and SEM. Final models are adjusted for baseline physical 
activity and total CAT score. Other potential confounders (age, gender, smoking habit, BMI, any COPD admissions in previous 12 
months, FEV1 % predicted, FVC % predicted, FEV1/FVC ratio, ATS/ERS stage, 6MWD, mMRC and HADS anxiety and depression 
scores) were tested and finally not included because they were not independently related to both the exposure and the outcome, 
nor modified (>10% change) the estimates for the remaining variables. * Patients without severe exacerbations. ** Irrespective of 
the number of moderate exacerbations. 
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